Biodesix, Inc.
BDSXNASDAQHealthcare● Active
$14.95
$-0.51(-3.30%)
Market Cap$121697171
P/E Ratio—
52W High$20.21
52W Low$5
Biodesix, Inc. (BDSX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BDSX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
-$0.81
Est. -$1.26 · +35.7%
Revenue
$0.03B
Est. $0.02B · +10.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
BDSX reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.88 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | May 4, 2026 | -$1.26 | -$0.81 | +35.7% | $0.03B | $0.02B | +10.5% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$1.05 | -$0.49 | +53.3% | $0.03B | $0.03B | +11.8% |
| ▲ Q4 FY2025 | Nov 3, 2025 | -$1.60 | -$1.16 | +27.5% | $0.02B | $0.03B | -17.1% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$1.40 | -$1.60 | -14.3% | $0.02B | $0.02B | +8.4% |
| — Q2 FY2025 | May 13, 2025 | -$0.08 | -$0.08 | +0.0% | $0.02B | $0.02B | -20.4% |
| ▲ Q1 FY2025 | Mar 3, 2025 | -$0.07 | -$0.06 | +14.3% | $0.02B | $0.02B | +0.5% |
| ▲ Q4 FY2024 | Nov 1, 2024 | -$0.08 | -$0.07 | +12.5% | $0.02B | $0.02B | -8.5% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.88
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Beat
EPS Actual
-$0.81
EPS Est.
-$1.26
EPS Surpr.
+35.7%
Revenue
$0.03B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.49
EPS Est.
-$1.05
EPS Surpr.
+53.3%
Revenue
$0.03B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
-$1.16
EPS Est.
-$1.60
EPS Surpr.
+27.5%
Revenue
$0.02B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$1.60
EPS Est.
-$1.40
EPS Surpr.
-14.3%
Revenue
$0.02B
Q2 FY2025
May 13, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.02B
Q1 FY2025
Mar 3, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.07
EPS Surpr.
+14.3%
Revenue
$0.02B
Q4 FY2024
Nov 1, 2024Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+12.5%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.27 | $-0.27 | $-0.26 | 1 |
| Q3 FY2027 | $-0.52 | $-0.51 | $-0.50 | 1 |
| Q2 FY2027 | $-0.63 | $-0.62 | $-0.60 | 1 |
| Q1 FY2027 | $-0.72 | $-0.70 | $-0.69 | 1 |
| Q4 FY2026 | $-0.50 | $-0.49 | $-0.48 | 1 |
| Q3 FY2026 | $-0.83 | $-0.81 | $-0.79 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 4, 2026 | +35.7% | $11.08 | $11.27 | +1.71% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +53.3% | $12.93 | $14.22 | +9.98% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +27.5% | $6.83 | $6.34 | -7.17% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -14.3% | $7.80 | $8.94 | +14.62% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $7.19 | $7.18 | -0.14% |
| ▲ Q1 FY2025 | Mar 3, 2025 | +14.3% | $15.86 | $14.26 | -10.09% |
| ▲ Q4 FY2024 | Nov 1, 2024 | +12.5% | $34.00 | $26.00 | -23.53% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +11.1% | $31.80 | $31.80 | +0.00% |
Q2 FY2026+1.71%
Report Date
May 4, 2026
EPS Beat/Miss
+35.7%
Price Before
$11.08
Price After
$11.27
Q1 FY2026+9.98%
Report Date
Feb 26, 2026
EPS Beat/Miss
+53.3%
Price Before
$12.93
Price After
$14.22
Q4 FY2025-7.17%
Report Date
Nov 3, 2025
EPS Beat/Miss
+27.5%
Price Before
$6.83
Price After
$6.34
Q3 FY2025+14.62%
Report Date
Aug 7, 2025
EPS Beat/Miss
-14.3%
Price Before
$7.80
Price After
$8.94
Q2 FY2025-0.14%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$7.19
Price After
$7.18
Q1 FY2025-10.09%
Report Date
Mar 3, 2025
EPS Beat/Miss
+14.3%
Price Before
$15.86
Price After
$14.26
Q4 FY2024-23.53%
Report Date
Nov 1, 2024
EPS Beat/Miss
+12.5%
Price Before
$34.00
Price After
$26.00
Q3 FY2024+0.00%
Report Date
Aug 7, 2024
EPS Beat/Miss
+11.1%
Price Before
$31.80
Price After
$31.80
Avg Beat Reaction-4.18%
Avg Miss Reaction+14.62%
Beat Rate7 / 8 quarters
Largest Move-23.53% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BDSX ends December
Biodesix, Inc. (BDSX) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $-0.81 — beating the analyst consensus of $-1.26 by +35.7%. BDSX has beaten EPS estimates for 3 consecutive quarters. The next BDSX earnings date is expected around September 1, 2026.
Each quarter, investors track BDSX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BDSX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BDSX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BDSX earnings · 5 questionsBiodesix, Inc.'s next earnings report is expected around September 1, 2026. BDSX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BDSX historically reports after market close (AMC).
BDSX earnings datewhen is BDSX earningsBDSX next earnings datewhen does BDSX report earningsBDSX earnings calendar
▸ Source: FMP · Biodesix, Inc. SEC filings · US GAAP · Biodesix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026